Calcium Channel Blocker Statement

Patient name		
Physician name		
Prior to the initiation of prostacyclin th The following calcium channel blocker		apy as follows.
 Calan® SR (verapamil) Cardene® (nicardipine) Cardizem® (diltiazem) 	 □ DynaCirc® (isradipine) □ Nimotop® (nimodipine) □ Norvasc® (amlodipine) 	 □ Plendil[®] (felodipine) □ Procardia[®] (nifedipine) □ Sular[®] (nisoldipine)
Other (specify)		_
With the following response:		
 Pressures continued to climb. Patient became hypotensive. Other (specify)	 Disease continued to progress. Patient had an allergic reaction. 	
A calcium channel blocker was not test	ed because:	
 Patient is hemodynamically unstable Patient did not respond to vasodilate pressure. Patient has systemic hypotension. Patient has depressed cardiac output 	or challenge with greater than 20% redu	iction in mean pulmonary artery
Other (specify)		_
Physician signature		
Date		

Fax completed form to 800.711.3526

All rights in the product names of all third-party products appearing in this document, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.

Amc4268 CRP 06062012

DID YOU RECEIVE THIS FAX BY MISTAKE?

Confidentiality Notice: This fax contains information from Accredo Health, Inc., and may include individual health information. The information is intended only for use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.